Company profile
Novavax, Inc.
NASDAQ: NVAX · Healthcare · Biotechnology
#147 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
69BFH 62DQ 84GM 50SS 86
v0.1 · 65/100 weight · provisional
↑ operating margin, return on assets · ↓ Piotroski F, 3-yr revenue growth
Methodology →Revenue TTM
$596.3M
Rev growth YoY (TTM)
-52.5%
Net income (FY)
$440.3M
Employees
749
as of 2026-08-09
Market cap
$1.3B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.1B$1.1B2025
Net income$440.3M$440.3M2025
Operating income$452.8M$452.8M2025
Total assets$1.2B$1.2B2025
Liabilities$1.3B$1.3B2025
Equity-$127.8M-$127.8M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product50%
Nuvaxovid Sales46%
Supply Sales4%
By geography
Rest of North America51%
UNITED STATES36%
Rest of the World11%
Europe1%
The read
What is Novavax, Inc.’s revenue?
Novavax, Inc. booked $1.1B in FY2025 revenue, growing 65% year over year — faster than most Healthcare companies we track, at a 39.2% net margin.
Peers · Healthcare
Trulieve Cannabis Corp.——Green Thumb Industries Inc.72BSotera Health Company70BBabylon Holdings Limited——Waystar Holding Corp.70BPrestige Consumer Healthcare Inc.78B+Neighbors
Montgomery →Key facts
CEOJohn Charles Jacobs
SectorHealthcare
IndustryBiotechnology
HeadquartersGaithersburg, MD
ExchangeNASDAQ: NVAX
Employees749
IPO date1995-12-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.